Fungizone (amphotericin B) Oral Suspension
January 1997
Bristol-Myers Squibb is finally marketing Fungizone (amphotericin B) Oral Suspension...for treating oral candidiasis.
This suspension was approved over 25 years ago. But it's just now being marketed because of the increasing incidence of oral candidiasis...particularly in patients with HIV or cancer.
Patients use the oral suspension QID...swish and swallow.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote